Nanotoxicity: The toxicity research progress of metal and metal-containing nanoparticles

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 7, 2015, Pages 529-542

  Ding, Lingling ^a   Liu, Zhidong ^a   Aggrey, Mike Okweesi ^b   Li, Chunhua ^a   Chen, Jing ^a   Tong, Ling ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF GHANA   (Ghana)

Author keywords

Influencing factors; Metal and metal containing nanoparticles; Reason and mechanism; Research methods; Toxicity expressive types; Toxicity research progress

Indexed keywords

METAL NANOPARTICLE; NANOPARTICLE; SURFACTANT; METAL;

ARTICLE; BLOOD TOXICITY; CARCINOGENIC ACTIVITY; CHEMICAL COMPOSITION; CYTOTOXICITY; DEGRADATION; EMBRYOTOXICITY; EVALUATION STUDY; GENOTOXICITY; HUMAN; IMMUNOTOXICITY; LIVER TOXICITY; LUNG TOXICITY; NANOTOXICOLOGY; NEPHROTOXICITY; NEUROVIRULENCE; PARTICLE SIZE; SURFACE CHARGE; ANIMAL; CELL LINE; CHEMISTRY; MUTAGEN TESTING;

ANIMALS; CELL LINE; HUMANS; METALS; MUTAGENICITY TESTS; NANOPARTICLES;

EID: 84929322828     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/138955751507150424104334     Document Type: Article

References (172)

1. Seda, T.; Aydin, R. Drug Targeting Systems for Cancer Therapy: Nanotechnological Approach. J. Mini-rev. Med. Chem., 2014, 14(13), 1048-1054.
2. Fadeel, B.; Garcia-Bennett, A.E. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. J. Adv. Drug Deliv. Rev., 2010, 62(3), 362-374.
3. Garnett, M. C; Kallinteri, P. Nanomedicines and nanotoxicology: some physiological Principles. J. Occup. Med., 2006, 56(5), 307- 311.
4. Oberdorster, G.; Oberdorster, E.; Oberdorster, J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. J. Env. Health Pers., 2005, 113 (7), 823-839.
5. Curtis, J.; Greenberg, M.; Kester, J.; Phillips, S.; Krieger, G. Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol. Sci., 2006, 25 (4), 245-260.
6. Bai, R. Targeting and adverse reactions of nanometer drugs. J. Clin. Rehab. Tissue Eng. Res., 2010, 14(8), 1463-1466.
7. Shi, Y.J.; Cheng, G. The research progress of nanoformulation biological safety evaluation. J. Shenyang Pharmaceut. Univ., 2010, 27(12), 987-992.
8. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Nanomedicine: current status and future prospects. J. FASEB, 2005, 19 (3), 311-330.
9. Italia, J.L.; Bhatt, D.K.; Bhardwaj, V.; Tikoo, K.; Kumar, M.N. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral. J. Cont. Rel., 2007, 119 (2), 197-206.
10. Namvar, F.; Rahman, H.S.; Mohamad, R. et al. Cytotoxic effect of magnetic iron oxide nanoparticles synthesized via seaweed aqueous extract. J. Intl. Nanomed., 2014, 9, 2479.
11. Ding, W.; Guo, L. Immobilized transferrin Fe3O4@ SiO2 nanoparticle with high doxorubicin loading for dual-targeted tumor drug delivery. J. Intl. Nanomed., 2013, 8, 4631.
12. Geng, F.; Xing, J.Z.; Chen, J. et al. Pegylated Glucose Gold Nanoparticles for Improved In-Vivo Bio-Distribution and Enhanced Radiotherapy on Cervical Cancer. J. Biomed. Nanotech., 2014, 10(7), 1205-1216.
13. Siqueira, M.C.; Coelho, G.F. de Moura, M.R. et al. Evaluation of Antimicrobial Activity of Silver Nanoparticles for Carboxymethylcellulose Film Applications in Food Packaging. J. Nanosci. Nanotech., 2014, 14(7), 5512-5517.
14. Jaroenworaluck, A.; Sunsaneeyametha, W.; Kosachan, N. et al. Characteristics of silica-coated TiO2 and its UV absorption for sunscreen cosmetic applications. J. Surface and Interface Analysis, 2006, 38(4), 473-477.
15. Grainger, D.W. Nanotoxicity assessment: all small talk?. J. Adv. Drug Deliv. Rev., 2009, 61(6), 419.
16. Liu, K.; Yue, X.; Zhao, J.S. Progress in research on toxicology of nanomaterials. J. Dep. Preventive Med., 2013, 17(1), 72-76.
17. Sayes, C. M.; Reed, K.L.; Warheit, D.B. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. J. Toxicol. Sci., 2007, 97(1), 163-180.
18. Li, S.D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. J. Mol. pharmaceut., 2008, 5(4), 496-504.
19. Xin, L.; Jiao, S. Endothelial cells dysfunction induced by silica nanoparticles through oxidative stress via JNK/P53 and NF-kB pathways. J. Biomat., 2010, 31, 8198-8209.
20. Ginzburg, V.V.; Balijepalli, S. Modeling the thermodynamics of the interaction of nanoparticles with cell membranes. J. Nano Lett., 2007, 7, 3716-3722.
21. Valdiglesias, V.; Costa, C.; Kilic, G. et al. Neuronal cytotoxicity and genotoxicity induced by zinc oxide nanoparticles. J. Env. Intl., 2013, 55, 92-100.
22. Sabella, S.; Carney, R. P.; Brunetti, V. et al. A general mechanism for intracellular toxicity of metal-containing nanoparticles. J. Nanoscale., 2014, 6(12), 7052-7061.
23. Stern, S. T.; Adiseshaiah, P. P.; Crist, R. M.; Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. J. Part. Fibre Toxicol., 2012, 9(1), 20.
24. Park, E. J.; Yi, J.; Kim, Y. et al. Silver nanoparticles induce cytotoxicity by a Trojan-horse type mechanism. J. Toxicol. in vitro, 2010, 24(3), 872-878.
25. Singh, N.; Manshian, B.; Jenkins, G.J.S. et al. Nano Genotoxicology: the DNA damaging potential of engineered nanomaterials. J. Biomat., 2009, 30(23): 3891-3914.
26. Hamzeh, M.; Sunahara, G. I. In vitro cytotoxicity and genotoxicity studies of titanium dioxide (TiO2) nanoparticles in Chinese hamster lung fibroblast cells. J. Toxicol. in vitro, 2013, 27(2), 864-873.
27. Guichard, Y.; Maire, M. A.; Sebillaud, S. et al. Genotoxicity of synthetic amorphous silica nanoparticles in rats following shortterm exposure, part 2: Intratracheal instillation and intravenous injection. J. Env. Mol. Mutagen., 2014.
28. Kumari, M.; Kumari, S. I.; Kamal, S. S. K. et al. Genotoxicity assessment of cerium oxide nanoparticles in female Wistar rats after acute oral exposure. J. Mut. Res./Gene. Toxicol. Env. Mutagen., 2014, 775, 7-19.
29. Ghosh, M.; Manivannan, J.; Sinha, S. et al. In vitro and in vivo genotoxicity of silver nanoparticles. J. Mut. Res./Gene. Toxicol. Env. Mutagen., 2012, 749(1), 60-69.
30. Xu, A.; Chai, Y.; Nohmi, T. et al. Genotoxic responses to titanium dioxide nanoparticles and fullerene in gpt delta transgenic MEF cells. J. Part. Fibre Toxicol., 2009, 6(3).
31. Oostingh, G. J.; Casals, E.; Italiani, P. et al. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. J. Part. Fibre Toxicol., 2011, 8(1), 8.
32. Cheng, C.; Mbller, K.H.; Koziol, K.K. et al. Toxicity and imaging of multi-walled carbon nanotubes in human macro-phage cells. J. Biomat., 2009, 30(25), 4152-4160.
33. Dobrovolskaiam, A.; Mcneil, S.E. Immunological prop-erties of engineered nanomaterials. J. Nat Nanotech., 2007, 2, 469-478.
34. Oostingh, G. J.; Casals, E. Italiani, P. et al. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. J. Part. Fibre Toxicol., 2011, 8(1), 8.
35. Liu, H.; Yang, D.; Yang, H. et al. Comparative study of respiratory tract immune toxicity induced by three sterilisation nanoparticles: silver, zinc oxide and titanium dioxide. J. Hazard. Mat., 2013, 248, 478-486.
36. MatEs, J.M.; Perez-Gomez, C.; De Castro, I.N. Antioxidant enzymes and human diseases. J. Clin. Biochem., 1999, 32(8), 595- 603.
37. Orringer, D.A.; Koo, Y.E.L.; Kopelman, R. et al. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. J. Clin. Pharmacol. Ther., 2009, 85(5), 531.
38. Karmakar, A.; Zhang, Q.; Zhang, Y. Neurotoxicity of nanoscale materials. J. Food & Drug Analysis, 2014, 22(1).
39. Shanker Sharma, H.; Sharma, A. Neurotoxicity of engineered nanoparticles from metals. J. CNS & Neurol. Disorders-Drug Targ. (Formerly Current Drug Targets-CNS & Neurological Disorders), 2012, 11(1), 65-80.
40. Kim, Y.; Kong, S. D.; Chen, L. H. et al. In vivo nanoneurotoxicity screening using oxidative stress and neuroinflammation paradigms. J. Nanomed.: Nanotechnol. Biol. Med., 2013, 9(7), 1057-1066.,.
41. Altmann, J.; Gubrud, M. Anticipating military nanotechnology. J. Tech. Soc. Magazine, IEEE., 2004, 23(4), 33-40.
42. Oberdorster, G.; Sharp, Z.; Atudorei, V. et al. Translocation of inhaled ultrafine particles to the brain. J. Inhal. Toxicol., 2004, 16, 437-445.
43. De Lorenzo, A.J.D. The olfactory neuron and the blood-brain barrier. In: Ciba Foundation symposium-internal secretions of the pancreas (colloquia on endocrinology). John Wiley & Sons: 2008, 151-176.
44. Tjalve, H.; Henriksson, J.; Tallkvist, J. et al. Uptake of manganese and cadmium from the nasal mucosa into the central nervous system via olfactory pathways in rats. J. Pharmacol. Toxicol., 1996, 79, 347-356.
45. Cho, W.S. ; Duffin, R. ; Poland, C.A. et al. Metal oxide nanoparticles induce unique inflammatory footprints in the lung: important implications for nanoparticle testing. J. Env. Health Perspect, 2010, 118, 1699-1706.
46. Darroudi, M.; Sabouri, Z.; Oskuee, R.K. et al. Neuronal toxicity of biopolymer-template synthesized ZnO nanoparticles. J. Nanomed., 2014, 1, 88-93.
47. Brenneman, K.A. ; Wong, B.A. ; Buccellato, M.A. et al. Direct olfactory transport of inhaled manganese ((54) MnCl2) to the rat brain: toxicokinetic investigations in a unilateral nasal occlusion model. Toxicol. Appl. Pharmacol., 2000, 169, 238-248.
48. Powers, C.M.; Badireddy, A.R.; RydeI, T. et al. Silver nanoparticles compromise neurodevelopment in PC12 cells: critical contributions of silver ion, particle size, coating, and composition. J. Env. Health Perspect, 2011, 119, 37-44.
49. Leung, M. C. K.; Williams, P. L.; Benedetto, A. et al. Caenorhabditis elegans: an emerging model in biomedical and environmental toxicology. J. Toxicol. Sci., 2008, 106(1), 5-28.
50. Yinxia, L.; Shunhui, Yu.; Quili, W.; Meng, Tang.; Yuepu, P.; Dayong, W. Chronic Al2O3-nanoparticle exposure causes neurotoxic effects on locomotion behaviors by inducing severe ROS production and disruption of ROS defense mechanisms in nematode Caenorhabditis elegans. J. Hazard. Mat., 2012, 3(83),221-230.
51. Wolfram, J.; Yang, Y.; Shen, J. et al. The nano-plasma interface: implications of the protein corona. J. Colloids and Surfaces B: Biointerfaces., 2014, 124, 17-24.
52. Zuo, G.; Kang, S.G.; Xiu, P.; Zhao, Y.; Zhou, R. Interactions between proteins and carbon-based nanoparticles: exploring the origin of nanotoxicity at the molec-ular level. J. Small, 2013, 9, 1546-1556.
53. Pelaz, B.; Charron, G.; Pfeiffer, C. et al. Interfacing engineered nanoparticles with biological systems: anticipating adverse nanobio interactions. J. Small, 2013, 9(9-10), 1573-1584.
54. Chiti, F.; Dobson, C. M. Protein misfolding, functional amyloid, and human disease. J. Annu. Rev. Biochem., 2006, 75: 333-366.
55. Ilinskaya & Dobrovolskaia. Nanoparticles and the blood coagulation system. Part II: safety concerns -a review. J. Nanomed., 2013, 8(6), 969-981.
56. Dobrovolskaia, M. A.; Neun, B. W.; Man, S. et al. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. J. Nanomed.: Nanotech. Biol. Med., 2014, 10(7), 1453-1463.
57. Brook, R.D.; Rajagopalan, S.; Pope, C.A. et al. Particulate matter air pollution and cardiovascular disease an update to the scientific statement from the American Heart Association. J. Circul., 2010, 121(21): 2331-2378.
58. Utell, M.J.; Frampton, M.W.; Zareba, W.; Devlin, R.B.; Cascio, W.E. Cardiovascular effects associated with air pollution: potential mechanisms and methods of testing. J. Inhal. Toxicol., 2002, 14(12), 1231-1247.
59. Ragaseema, V.M.; Unnikrishnan, S.; Kalliyana, Krishnan, V. et al. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces. J. Biomat., 2012, 33(11), 3083- 3092.
60. Shrivastava, S.; Bera, T.; Singh, S.K. et al. Characterization of antiplatelet properties of silver nanoparticles. J. ACS Nano., 2009, 3(6), 1357-1364.
61. Tavano, R.; Segat, D.; Reddi, E. et al. Procoagulant properties of bare and highly PEGylated vinyl-modified silica nanoparticles. J. Nanomed., 2010, 5(6), 881-896.
62. Dobrovolskaia, M. A.; Neun, B. W.; Man, S. et al. Protein corona composition does not accurately predict hematocompatibility of colloidal gold nanoparticles. J. Nanomed.: Nanotech. Biol. Med., 2014, 10(7), 1453-1463.
63. Lee, W. M. Drug-induced hepatotoxicity. J. New Eng. Med., 2003, 349(5), 474-485.
64. Winwood, P. J.; Arthur, M. J. Kupffer cells: their activation and role in animal models of liver injury and human liver disease. C. Sem. Liver Dis., 1993, 13(1), 50.
65. Liu, C.; Tao, Q.; Sun M. et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. J. Lab. Invest., 2010, 90(12), 1805-1816.
66. Thakur, V.; McMullen, M. R.; Pritchard, M. T. et al. Regulation of macrophage activation in alcoholic liver disease. J. Gastroenterol. Hepatol., 2007, 22(1), 53-56.
67. HYLAND, B. J.; SIMMONS, R. L. Evidence that rat Kupffer cells stimulate and inhibit hepatocyte protein synthesis in vitro by different mechanisms. J. Gastroenterol., 1989, 98, 1572-1582.
68. Laskin, D. L.; Gardner, C. R.; Price, V. F. et al. Modulation of macrophage functioning abrogates the acute hepatotoxicity of acetaminophen. J. Hepatol., 1995, 21(4), 1045-1050.
69. Roberts, R.A.; Ganey, P.E.; Ju, C.; Kamendulis, L.M.; Rusyn, I.; Klaunig, J.E. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci., 2007, 96, 2-15.
70. Chen, Q.; Xue, Y.; Sun, J. Kupffer cell-mediated hepatic injury induced by silica nanoparticles in vitro and in vivo. J. Intl. Nanomed., 2013, 8, 1129.
71. Sha, B.; Gao, W.; Wang, S. et al. Oxidative stress increased hepatotoxicity induced by nano-titanium dioxide in BRL-3A cells and Sprague-Dawley rats. J. Appl. Toxicol., 2014, 34(4), 345- 356.
72. Heydrnejad, M. S.; Samani, R. J.; Aghaeivanda, S. Toxic Effects of Silver Nanoparticles on Liver and Some Hematological Parameters in Male and Female Mice (Mus musculus). J. Biol. trace element res., 2015, 1-6.
73. Barbier, O.; Jacquillet, G.; Tauc, M. et al. Effect of heavy metals on, and handling by, the kidney. J. Nephron Physiol., 2005, 99(4), 105-110.
74. Huang, C.; Aronstam, R.; Chen, D.; Huang, Y. Oxidative stress, calcium homeostasis, and altered gene expression in human lung epithelial cells exposed to ZnO nanoparticles. Toxicol. in vitro., 2010, 24, 45-55.
75. Costello, L.; Franklin, R.; Feng, P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion, 2005, 5, 143-153.
76. Waldbaum, S.; Patel, M. Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res., 2010, 88, 23-45.
77. Wang, B.; Feng, W.; Wang, T.; Jia, G.; Wang, M.; Shi, J.; Zhang, F.; Zhao, Y.; Chai, Z. Acute toxicity of nano-and micro-scale zinc powder in healthy adult mice. Toxicol. Lett., 2006, 161, 115-123.
78. Liao, M. Y.; Liu, H. G. Gene expression profiling of nephrotoxicity from copper nanoparticles in rats after repeated oral administration. J. Env. Toxicol. Pharmacol., 2012, 34(1), 67-80.
79. Yan, G.; Huang, Y.; Bu, Q. et al. Zinc oxide nanoparticles cause nephrotoxicity and kidney metabolism alterations in rats. J. Env. Sci. Health, Part A, 2012, 47(4), 577-588.
80. Akgun, H.; Gonlusen, G.; Cartwright, J.J. et al. Are gadoliniumbased contrast media nephrotoxic? : A renal biopsy study. J. Arch. Pathol. Lab. Med., 2006, 130(9), 1354-1357.
81. Sopjani, M.; Foller, M.; Lang, F. Gold stimulates Ca2+ entry into and subsequent suicidal death of erythrocytes. J. Toxicol., 2008, 244, 271-279.
82. Sereemaspun, A.; Rojanathanes, R.; Wiwanitkit, V. Effect of gold nanoparticle on renal cell: an implication for exposure risk. J. Renal Failure, 2008, 30(3), 323-325.
83. Yamagishi, Y.; Watari, A.; Hayata, Y. et al. Acute and chronic nephrotoxicity of platinum nanoparticles in mice. J. Nanoscale Res. lett., 2013, 8(1), 1-7.
84. Nurkiewicz, T. R.; Porter, D. W.; Hubbs, A. F. et al. Pulmonary particulate matter and systemic microvascular dysfunction. J. Research report (Health Effects Institute), 2011 (164), 3-48.
85. Simeonova, P. P.; Erdely, A. Engineered nanoparticle respiratory exposure and potential risks for cardiovascular toxicity: predictive tests and biomarkers. J. Inhal. Toxicol., 2009, 21(1), 68-73.
86. Li, J. J.; Muralikrishnan, S.; Ng, C. T. et al. Nanoparticle-induced pulmonary toxicity. J. Exper. Biol. med., 2010, 235(9), 1025-1033.
87. Song, Y.; Li, X.; Du, X. Exposure to nanoparticles is related to pleural effusion, pulmonary fibrosis and granuloma. J. Euro. Resp., 2009, 34(3), 559-567.
88. Armstead, A. L.; Arena, C. B.; Li, B. Exploring the potential role of tungsten carbide cobalt (WC-Co) nanoparticle internalization in observed toxicity toward lung epithelial cells in vitro. J. Toxicol. Appl. Pharmacol., 2014, 278(1), 1-8.
89. Arai, Y.; Miyayama, T.; Hirano, S. Difference in the toxicity mechanism between ion and nanoparticle forms of silver in the mouse lung and in macrophages. J. Toxicol., 2015, 328, 84-92.
90. Cho, W. S.; Duffin, R.; Bradley, M. et al. Predictive value of in vitro assays depends on the mechanism of toxicity of metal oxide nanoparticles. J. Part. Fibre Toxicol., 2013, 10, 55.
91. Schlinkert, P.; Casals, E.; Boyles, M. et al. The oxidative potential of differently charged silver and gold nanoparticles on three human lung epithelial cell types. J. Nanobiotech., 2015 (1), 1.
92. Pott, F.; Roller, M. Carcinogenicity study with nineteen granular dusts in rats. J. Eur. J. Oncol., 2005, 10, 249-282.
93. Liu, H.G.; Bai, W.; Zhang, Z.Y. et al. Effects of several nanooxidets on the hatching rate of zebrafish embryos. J. China Env. Sci., 2009, 29(1), 53-57.
94. Browning, L.M.; Lee, K.J.; Nallathamby, P.D. et al. Silver Nanoparticles Incite Size-and Dose-Dependent Developmental Phenotypes and Nanotoxicity in Zebrafish Embryos. J. Chem. res. toxicol., 2013, 26(10), 1503-1513.
95. Oberdorster, G. Biokinetics and effects of nanoparticles [M]//Nanotechnology-toxicological issues and environmental safety and environmental safety. Springer Netherlands, 2007, 15- 51.
96. Aggarwal, P.; Hall, J.B.; McLeland, C.B. et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. J. Adv. Drug Deliv. Rev., 2009, 61(6): 428-437.
97. Sabella, S.; Carney, R.P.; Brunetti, V. et al. A general mechanism for intracellular toxicity of metal-containing nanoparticles. J. Nanoscale., 2014, 6(12), 7052-7061.
98. Arbab, A.S.; Wilson, L.B.; Ashari, P. et al. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. J. NMR in Biomed., 2005, 18(6), 383-389.
99. L´evy, M. et al. Degradability of superparamagnetic nanoparticles in a model of intracellular environment: follow-up of magnetic, structural and chemical properties. J. Nanotech., 2010, 21, 395103.
100. Nel, A.E.; Madler, L.; Velegol, D. et al. Understanding biophysicochemical interactions at the nano-bio interface. J. Nat. Mat., 2009, 8(7), 543-557.
101. Xia, T.et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. J. Nano. Lett., 2006, 6, 1794-1807.
102. Deng, Z.J.; Liang, M.; Monteiro, M.; Toth, I.; Minchin, R. F. Nanoparticle-induced unfolding of brinogen promotes Mac-1 receptor activation and in ammation, Nat. Nanotech., 2011, 6, 39- 44.
103. Aggarwal, P.; Hall, J.B.; McLeland, C.B. et al. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. J. Adv. Drug Deliv. Rev., 2009, 61(6), 428-437.
104. Aillon, K.L.; Xie, Y.; El-Gendy, N. et al. Effects of nanomaterial physicochemical properties on in vivo toxicity. J. Adv. drug deliv. rev., 2009, 61(6): 457-466.
105. Cedervall, T.; Lynch, I.; Lindman, S. et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. J. Proc. Nat. Acad. Sci., 2007, 104(7), 2050-2055.
106. Maiorano, G.; Sabella, S.; Sorce, B. et al. Effects of cell culture media on the dynamic formation of protein- nanoparticle complexes and influence on the cellular response. J. ACS nano., 2010, 4(12), 7481-7491.
107. Lesniak, A.; Fenaroli, F. ; Monopoli, M.P. et al. Effects of the presence or absence of a protein corona on silica nanoparticle uptake and impact on cells. J. ACS Nano., 2012, 6(7), 5845-5857.
108. Ge, C. ; Du, J. ; Zhao, L. et al. Binding of blood proteins to carbon nanotubes reduces cytotoxicity. J. Proc. Nat. Acad. Sci., 2011, 108(41), 16968-16973.
109. Wang, F.; Yu, L.; Monopoli, M.P. et al. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. J. Nanomed.: Nanotech. Biol. Med., 2013, 9(8), 1159- 1168.
110. Hu, W.; Peng, C.; Lv, M. et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. J. Acs Nano., 2011, 5(5), 3693- 3700.
111. Xia, T. ; Kovochich, M. ; Liong, M. et al. Cationic polystyrene nanosphere toxicity depends on cell-specific endocytic and mitochondrial injury pathways. J. ACS Nano., 2007, 2(1), 85-96.
112. Stern, S.T.; Adiseshaiah, P.P.; Crist, R.M. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. J. Part. Fibre Toxicol., 2012, 9(1), 20.
113. Liu, J.; Hurt, R.H. Ion release kinetics and particle persistence in aqueous nano-silver colloids. J. Env. Sci. tech., 2010, 44(6), 2169- 2175.
114. Lanone, S.; Boczkowski, J. Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. J. Curr. Mol. Med., 2006, 6(6), 651-663.
115. Mohanraj, V.J.; Chen, Y. Nanoparticles-a review. J. Tropi. Pharmaceut. Res., 2007, 5(1), 561-573.
116. Rejman, J.; Oberle, V.; Zuhorn, I.S.; Hoekstra, D. Size-dependent internalization of particles via the pathways of clarthrin- and caveolae-mediated endocytosis. J. Biochem., 2004, 377, 159-169.
117. De Jong, W.H.; Hagens, W.I.; Krystek, P. et al. Particle sizedependent organ distribution of gold nanoparticles after intravenous administration. J. Biomat., 2008, 29(12), 1912-1919.
118. Garnett, M.C.; Kallinteri, P. Nanomedicines and nanotoxicity: some physiological principles, Occup. J. Med., 2006, 56, 307-311.
119. Ballou, B.; Lagerholm, B.C.; Ernst, L.A. et al. Noninvasive imaging of quantum dots in mice. J. Bioconjugate Chem., 2004, 15(1), 79-86.
120. Fischer, H.C.; Chan, W.; C, W. Nanotoxicity: the growing need for in vivo study. J. Curr. Opin. Biotechnol., 2007, 18(6), 565-571.
121. Guo, L.; Panderi, I.; Yan, D.D. et al. A comparative study of hollow copper sulfide nanoparticles and hollow gold nanospheres on degradability and toxicity. J. ACS Nano., 2013, 7(10), 8780- 8793.
122. Truong, L.; Saili, K.S.; Miller, J. M. et al. Persistent adult zebrafish behavioral deficits results from acute embryonic exposure to gold nanoparticles. J. Comparative Biochem. Physiol. Part C: Toxicol. Pharmacol., 2012, 155(2), 269-274.
123. Chithrani, B.D.; Ghazani, A.A.; Chan, W.; C, W. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. J. Nano. lett., 2006, 6(4), 662-668.
124. Porter, D.W. ; Wu, N. ; Hubbs, A. et al. Differential mouse pulmonary dose-and time course-responses to titanium dioxide nanospheres and nanobelts. J. Toxicol. Sci., 2012, 261.
125. Shvedova, A.A.; Kisin, E.R.; Mercer, R. et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. J. Amer. Physiol. Lung Cell. Mol. Physiol., 2005, 289(5), L698-L708.
126. Stoehr, L.C.; Gonzalez, E.; Stampfl, A. et al. Shape matters: effects of silver nanospheres and wires on human alveolar epithelial cells. J. Part. Fibre Toxicol., 2011, 8(36), 3-15.
127. Antonietti, M. Surfactants for novel templating applications. J. Curr. Opin. Coll. Interface Sci., 2001, 6(3), 244-248.
128. John, V.T.; Simmons, B.; McPherson, G.L.; Bose, A. Recent developments in materials synthesis in surfactant systems. J. Curr. Opin. Coll. Interface Sci., 2002, 7, 288-295.
129. Jain, T.K.; Morales, M.A.; Sahoo, S.K.; Leslie-Pelecky, D.L.; Labhasetwar, V. Iron oxide nanoparticles for sustained delivery of anticancer agents. J. Mol. Pharm., 2005, 2, 194-205.
130. Wang, D.; Lin, Z.; Yao, Z. et al. Surfactants present complex joint effects on the toxicities of metal oxide nanoparticles. J. Chemosphere., 2014, 108, 70-75.
131. Schreier, S.; Malheiros, S.V.P.; de Paula, E. Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects. J. Biochimica et Biophysica Acta (BBA)-Biomembranes., 2000, 1508(1), 210-234.
132. Lovern, S.B.; Klaper, R. Daphnia magna mortality when exposed to titanium dioxide and fullerene (C60) nanoparticles. J. Env. Toxicol. Chem., 2006, 25(4), 1132-1137.
133. Baalousha, M. Aggregation and disaggregation of iron oxide nanoparticles: influence of particle concentration, pH and natural organic matter. J. Sci. Total Env., 2009, 407(6), 2093-2101.
134. Zhang, L.W.; Zeng, L.; Barron, A.R. et al. Biological interactions of functionalized single-wall carbon nanotubes in human epidermal keratinocytes. J. Intl. Toxicol., 2007, 26(2), 103-113.
135. Zhang, X. D.; Wu, H. Y.; Wu, D. et al. Toxicologic effects of gold nanoparticles in vivo by different administration routes. J. Intl. nanomed., 2010, 5, 771.
136. Singh, S.; Shi, T.; Duffin, R. et al. Endocytosis, oxidative stress and IL-8 expression in human lung epithelial cells upon treatment with fine and ultrafine TiO2: role of the specific surface area and of surface methylation of the particles. J. Toxicol. Applied Pharmacol., 2007, 222(2), 141-151.
137. Clift, M. J. D.; Rothen-Rutishauser, B.; Brown, D. M. et al. The impact of different nanoparticle surface chemistry and size on uptake and toxicity in a murine macrophage cell line. J. Toxicol. Appl. Pharmacol., 2008, 232(3), 418-427.
138. Oberdorster, G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Internal Med., 2010, 267(1), 89-105.
139. Nel, A.; Xia, T.; Madler, L. et al. Toxic potential of materials at the nanolevel. J. Sci., 2006, 311(5761), 622-627.
140. Lewinski, N.; Colvin, V.; Drezek, R. Cytotoxicity of nanoparticles. J. Small., 2008, 4(1), 26-49.
141. Lewis, A.L.; Driver, M. Blending in with the body. J. chem. edu., 2002, 79(3), 321.
142. Stern, S.T.; McNeil, S.E. Nanotechnology safety concerns revisited. J. Toxicol. Sci., 2008, 101(1), 4-21.
143. Jones, C.F.; Grainger, D.W. In vitro assessments of nanomaterial toxicity. J. Adv. Drug Deliv. Rev., 2009, 61(6), 438-456.
144. Moghimi, S.M.; Patel, H.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. J. Adv. Drug Deliv. Rev., 1998, 32(1), 45-60.
145. Lemaire, F.; Mandon, C.A.; Reboud, J. et al. Toxicity assays in nanodrops combining bioassay and morphometric endpoints. J. PloS one, 2007, 2(1), e163.
146. Hussain, S.M.; Hess, K.L.; Gearhart, J.M. et al. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. J. Toxicol. in vitro, 2005, 19(7), 975-983.
147. Veranth, J.M. In vitro Models for Nanoparticle Toxicology, in Nanoscience and Nanotechnology, Grassian, V.H. Editor.; 2008, John Wiley & Sons, Inc.
148. Jan, E. et al. High-content Screening as a Universal Tool for Fingerprinting of Cytotoxicity of Nanoparticles. J. ACS Nano., 2008.
149. Wilson, M.R.; Lightbody, J.H.; Donaldson, K. et al. Interactions between Ultrafine Particles and Transition Metals in vivo and in vitro. J. Toxicol. Applied Pharmacol., 2002, 184(3), 172-179.
150. Lin, W.; Huang, Y.; Zhou, X.D. et al. In vitro toxicity of silica nanoparticles in human lung cancer cells. J. Toxicol. applied pharmacol., 2006, 217(3), 252-259.
151. Monteiller, C.; Tran, L.; MacNee, W. et al. The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. J. Occup. Env. Med., 2007, 64(9), 609-615.
152. Schins, R.P.F.; Duffin, R.; Hohr, D. et al. Surface modification of quartz inhibits toxicity, particle uptake, and oxidative DNA damage in human lung epithelial cells. J. Chem. Res. Toxicol., 2002, 15(9), 1166-1173.
153. Tian, F.; Cui, D.; Schwarz, H. et al. Cytotoxicity of single-wall carbon nanotubes on human fibroblasts. J. Toxicol. in vitro., 2006, 20(7), 1202-1212.
154. Choi, A.O.; Cho, S.J.; Desbarats, J. et al. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J. nanobiotechnol., 2007, 5(1), 1.
155. Dong, L.; Joseph, K.L.; Witkowski, C.M. et al. Cytotoxicity of single-walled carbon nanotubes suspended in various surfactants. J. Nanotechnol., 2008, 19(25), 255702.
156. Davoren, M.; Herzog, E.; Casey, A. et al. In vitro toxicity evaluation of single walled carbon nanotubes on human A549 lung cells. J. Toxicol. in vitro., 2007, 21(3), 438-448.
157. Long, T.C.; Tajuba, J.; Sama, P. et al. Nanosize titanium dioxide stimulates reactive oxygen species in brain microglia and damages neurons in vitro. J. Env. Health Persp., 2007, 1631-1637.
158. Severino, P.; Andreani, T.; Jager, A. et al. Solid lipid nanoparticles for hydrophilic biotech drugs: Optimization and cell viability studies (Caco-2 & HEPG-2 cell lines). J. Euro. Med. Chem., 2014, 81, 28-34.
159. Oesterling, E.; Chopra, N.; Gavalas, V. et al. Alumina nanoparticles induce expression of endothelial cell adhesion molecules. J. Toxicol. Lett., 2008, 178(3), 160-166.
160. Arenz, A.; Hellweg, C.E.; Stojicic, N. et al. Gene Expression Modulation in A549 Human Lung Cells in Response to Combustion-Generated Nano-Sized Particles. J. Ann. New York Acad. Sci., 2006, 1091(1), 170-183.
161. Sivakumar Balasubramanian, A.R.G.; Nagaoka, Y.; Iwai, S. et al. Curcumin and 5-Fluorouracil-loaded, folate-and transferrindecorated polymeric magnetic nanoformulation: a synergistic cancer therapeutic approach, accelerated by magnetic hyperthermia. J. Intl. Nanomed., 2014, 9, 437.
162. Rothen-Rutishauser, B.M.; Church, S.; Haenni, B. et al. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. J. Env. Sci. Technol., 2006, 40(14), 4353-4359.
163. O'brien, P.J. ; Irwin, W. ; Diaz, D. et al. High concordance of druginduced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening. J. Arch. toxicol., 2006, 80(9), 580-604.
164. Xu, J.J.; Henstock, P.V.; Dunn, M.C. et al. Cellular imaging predictions of clinical drug-induced liver injury. J. Toxicol. Sci., 2008, 105(1), 97-105.
165. Persson, M.; Lye, A.F.; Mow, T. et al. A high content screening assay to predict human drug-induced liver injury during drug discovery. J. pharmacol. Toxicol. Methods, 2013, 68(3), 302-313.
166. Yildirimer, L.; Thanh, N.T.K.; Loizidou, M. et al. Toxicology and clinical potential of nanoparticles. J. Nano Today., 2011, 6(6), 585- 607.
167. Liu, L.; Hitchens, T.K. ; Ye, Q. et al. Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano-and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. J. Biochimica et Biophysica Acta (BBA)-General Subjects, 2013, 1830(6), 3447- 3453.
168. Park, E.J.; Sim, J.; Kim, Y. et al. A 13-week repeated-dose oral toxicity and bioaccumulation of aluminum oxide nanoparticles in mice. J. Arch. Toxicol., 2014, 1-9.
169. Sayes, C.M.; Reed, K.L.; Warheit, D.B. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. J. Toxicol. Sci., 2007, 97(1), 163-180.
170. Faraji, A.H.; Wipf, P. Nanoparticles in cellular drug delivery. J. Bioorg. Med. Chem., 2009, 17(8), 2950-2962.
171. Li, Y.F.; Chen, C. Fate and Toxicity of Metallic and Metal Containing Nanoparticles for Biomedical Applications. J. Small., 2011, 7(21), 2965-2980.
172. Ma-Hock, L.; Burkhardt, S.; Strauss, V. et al. Development of a short-term inhalation test in the rat using nano-titanium dioxide as a model substance. J. Inhal. Toxicol., 2009, 21(2),102-118.